📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-06 20:05
0 analysed today
FollowTelegram
0
Today
151,853
All-time analysed
43,533
Positive
6,742
Negative
92,741
Neutral
8,769
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
4 announcements match the current filters (relevance ≥ 5).
24.4% YoY PAT Decline to ₹5.89 Cr; Revenue Stagnant at ₹35.51 Cr
Jenburkt Pharmaceuticals reported a weak Q1 FY27 with Profit After Tax (PAT) declining 24.4% YoY to ₹5.89 Cr, down from ₹7.79 Cr in the year-ago period. Revenue from operations remained virtually flat at ₹35.51 Cr compared to ₹35.53 Cr YoY, while sequentially it dropped 20.4% from ₹44.63 Cr in March 2026. The profitability was severely impacted by a 10.4% YoY increase in total expenses, specifically driven by higher employee costs and other operating expenses. Consequently, the EPS for the quarter fell to ₹13.34 from ₹17.66 YoY.
Confidence: HIGH
What changedThe company experienced a significant margin squeeze in Q1 FY27, with profits falling sharply despite stable revenue, primarily due to rising operational and personnel costs.
Why it mattersFor a small-cap pharmaceutical company with a ₹517 Cr market cap, a 24% drop in quarterly profit indicates vulnerability to cost inflation and limited pricing power under regulatory controls like DPCO.
Revenue from Operations: ₹35.51 CrProfit After Tax: ₹5.89 CrEPS (Q1): ₹13.34Employee Cost as % of Revenue: 36.7%YoY PAT Growth: -24.4%
📅 Short termThe stock may face downward pressure in the short term as the market reacts to the sharp decline in profitability and lack of revenue growth.
📈 Long termThe long-term outlook depends on the company's ability to scale its international business and successfully implement its 'organizational refresh' to improve agility and margins.
⚠ Risk flags
- Margin compression due to rising operating expenses
- Stagnant revenue growth
- High employee cost ratio
- Regulatory price controls (NPPA/DPCO) limiting pricing flexibility
Key Highlights
Net Profit (PAT) fell 24.4% YoY to ₹5.89 Cr from ₹7.79 Cr.
Revenue from operations was stagnant at ₹35.51 Cr vs ₹35.53 Cr in the same quarter last year.
Other expenses surged 21.7% YoY to ₹10.14 Cr from ₹8.33 Cr.
Employee benefit expenses increased 11.1% YoY to ₹13.03 Cr.
Profit Before Tax (PBT) margin contracted significantly to 18.3% from 27.1% YoY.
👀 What to Watch
Investors should monitor the company's ability to manage rising operating costs and employee expenses, which are currently outpacing revenue growth. Watch for updates on international expansion and new product launches to see if they can revitalize the stagnant top-line.
24.4% YoY PAT Decline in Q1 FY27; Revenue Stagnant at ₹35.51 Cr
Jenburkt Pharmaceuticals reported a weak start to FY27 with Net Profit (PAT) declining 24.4% YoY to ₹5.89 Cr. Revenue from operations remained flat at ₹35.51 Cr compared to ₹35.53 Cr in the year-ago period. Profitability was significantly impacted by a 21.7% rise in other expenses and an 11.1% increase in employee benefit costs. Sequentially, revenue saw a sharp 20.4% drop from the ₹44.63 Cr recorded in the March 2026 quarter.
Confidence: HIGH
What changedThe company transitioned from a high-growth FY26 (PAT ₹35 Cr) to a margin-compressed Q1 FY27, with profits falling despite stable revenue.
Why it mattersThe sharp decline in PAT and stagnant revenue suggests that rising costs (employee and other expenses) are outpacing the company's pricing power or volume growth, potentially impacting its historical 25% operating margins.
Revenue (Q1 FY27): ₹35.51 CrPAT (Q1 FY27): ₹5.89 CrYoY PAT Growth: -24.4%QoQ Revenue Growth: -20.4%Employee Cost as % of Revenue: 36.7%
📅 Short termThe stock may face downward pressure in the short term as the market reacts to the significant profit contraction and lack of top-line growth.
📈 Long termWhile the company remains virtually debt-free with a strong ROCE (27%), long-term value creation depends on its ability to scale international business and successfully launch new products to offset domestic pricing pressures.
⚠ Risk flags
- Rising operational expenses (Other Expenses up 21.7% YoY)
- Stagnant revenue growth
- High employee cost concentration relative to revenue
Key Highlights
Revenue from operations remained stagnant at ₹35.51 Cr vs ₹35.53 Cr YoY.
Net Profit (PAT) fell to ₹5.89 Cr, a 24.4% decline from ₹7.79 Cr in Q1 FY26.
Employee benefit expenses rose to ₹13.03 Cr, representing 36.7% of revenue.
Other expenses increased by ₹1.81 Cr YoY to reach ₹10.14 Cr.
Basic EPS for the quarter dropped to ₹13.34 from ₹17.66 YoY.
👀 What to Watch
Investors should monitor the company's ability to control rising operational costs and track if the sequential revenue drop is seasonal or indicative of slowing demand in key therapeutic segments.
₹20.70 Dividend Proposed; AGM Set for Sept 4, 2026; CWIP at ₹46.12 Cr
Jenburkt Pharmaceuticals has scheduled its 41st AGM for September 4, 2026, and proposed a dividend of ₹20.70 per share (207% of face value). For FY26, the company reported revenue of ₹168.74 Cr, an 11% increase YoY, with a PAT of ₹34.74 Cr. A significant highlight is the Capital Work in Progress (CWIP) of ₹46.12 Cr, which represents approximately 27% of FY26 revenue, indicating substantial ongoing investment in modernization. The company remains virtually debt-free with a net worth of ₹197.04 Cr.
Confidence: HIGH
What changedThe company has formalized its annual shareholder meeting, declared its final dividend for FY26, and disclosed its full audited financial position including a significant increase in capital work in progress.
Why it mattersThe announcement confirms a steady dividend payout and reveals significant capital expenditure (CWIP is ~27% of revenue) which is material for a small-cap company aiming for 8-10% growth.
Dividend per share: ₹20.70FY26 Revenue: ₹168.74 CrCapital Work in Progress (CWIP): ₹46.12 CrCWIP vs FY26 Revenue: 27.33%Net Worth: ₹197.04 CrCost Auditor Remuneration: ₹2,75,000
📅 Short termThe stock may see minor interest due to the dividend yield (approx 1.9% at current price), but the AGM notice is largely a procedural event.
📈 Long termThe company's focus on modernization through the RPTUAS scheme and its debt-free status provide a stable foundation, though growth remains capped by regulatory price controls.
⚠ Risk flags
- Critical dependence on China for APIs
- Pricing pressure from NPPA/DPCO controls
- Key management person (CFO) is 74 years old
Key Highlights
Proposed dividend of ₹20.70 per equity share for the financial year ended March 31, 2026.
FY26 Revenue from operations grew to ₹168.74 Cr from ₹151.69 Cr in the previous year.
Capital Work in Progress (CWIP) stands at ₹46.12 Cr, representing 23.4% of the company's Net Worth.
Re-appointment of Shri Dilip H. Bhuta (74 years) as Whole Time Director and CFO for a 5-year term starting April 2027.
Total investments increased to ₹27.02 Cr in FY26 from ₹20.56 Cr in FY25.
👀 What to Watch
Investors should monitor the timeline for the conversion of the ₹46.12 Cr CWIP into operational assets, as this modernization is key to maintaining the company's 27% ROCE.
₹20.70 Dividend Declared; FY26 Revenue Grows 11% to ₹168.7 Cr with Significant CWIP
Jenburkt Pharmaceuticals has released its FY26 Annual Report, confirming a dividend of ₹20.70 per share (207% on face value). The company reported an 11.2% YoY revenue growth to ₹168.74 Cr and an 8.4% increase in PAT to ₹34.74 Cr. A notable highlight is the Capital Work in Progress (CWIP) of ₹46.12 Cr, which is approximately 23.4% of the company's net worth, indicating substantial ongoing investment in modernization or capacity. The 41st AGM is scheduled for September 4, 2026.
Confidence: HIGH
What changedThe company has formalized its FY26 financial results and dividend through the Annual Report and scheduled its 41st Annual General Meeting.
Why it mattersThe report confirms steady financial growth and reveals a high level of capital expenditure (CWIP) relative to the company's current asset base, suggesting future capacity expansion.
Dividend per share: ₹20.70FY26 Revenue: ₹168.74 CrCWIP vs Net Worth: 23.4%FY26 PAT: ₹34.74 CrAGM Date: 04th September, 2026
📅 Short termThe stock may see minor interest due to the dividend confirmation, but the impact is likely already priced in from previous quarterly results.
📈 Long termThe significant investment in CWIP (₹46.12 Cr) is structurally important and could lead to a re-rating if it results in higher-margin product launches or expanded export capacity.
⚠ Risk flags
- Execution risk related to the high CWIP
- Pricing pressure from NPPA/DPCO on essential medicines
- Dependence on China for APIs
Key Highlights
Proposed dividend of ₹20.70 per equity share for FY 2025-26.
Annual revenue from operations increased to ₹168.74 Cr from ₹151.69 Cr in the previous year.
Capital Work in Progress (CWIP) stands at ₹46.12 Cr, significantly higher than Net Fixed Assets of ₹19.46 Cr.
Net worth improved to ₹197.04 Cr as of March 31, 2026, from ₹171.78 Cr in FY25.
Re-appointment of Shri Dilip H. Bhuta as Whole Time Director and CFO for a 5-year term starting April 2027.
👀 What to Watch
Investors should monitor the timeline for the commissioning of the ₹46.12 Cr CWIP, as this represents a major asset expansion that could drive future revenue growth.
